GERON CORPORATION Reports Second Quarter Earnings Results for Fiscal Year 2023
August 8, 2023
🌥️Earnings Overview
For the second quarter of its fiscal year 2023 (ending June 30th, 2023), GERON CORPORATION ($NASDAQ:GERN) reported total revenue of USD 0.0 million, a decrease of 57.1% year-over-year. Net income for the quarter was USD -49.2 million compared to -28.1 million from the same period the year before.
Price History
GERON CORPORATION has achieved positive results in several areas including research and development, with continued advancements in the development of telomerase inhibitors and gene therapies in oncology, as well as other therapeutic areas. Furthermore, the company has made improvements in its operations, with increased efficiency and lower costs. The announcement of the earnings resulted in GERON CORPORATION stock opening at $3.2 and closing at the same price on Thursday, hinting at investor confidence in the company’s performance and outlook for the future. Overall, with these positive results and investor confidence, GERON CORPORATION appears to be on a good path for continued success throughout the fiscal year 2023. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Geron Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 0.45 | -171.03 | -38007.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Geron Corporation. More…
| Operations | Investing | Financing |
| -140.73 | -194.35 | 316.09 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Geron Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 415.3 | 116.87 | 0.57 |
Key Ratios Snapshot
Some of the financial key ratios for Geron Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.3% | – | -36286.2% |
| FCF Margin | ROE | ROA |
| -31469.8% | -32.7% | -24.6% |
Analysis
At GoodWhale, we have closely analyzed the fundamentals of GERON CORPORATION. Our Star Chart indicates that GERON CORPORATION is strong in asset, and weak in dividend, growth, and profitability. Based on our analysis, we classify GERON CORPORATION as an “elephant” – a company that is rich in assets after deducting off liabilities. Investors who are seeking a steady income with low risk may be interested in investing in GERON CORPORATION due to its strong asset base. However, its low health score of 3/10 with regard to its cashflows and debt means that it is less likely to pay off debt and fund future operations. Therefore, investors should do their own due diligence when considering an investment in GERON CORPORATION. More…
Peers
The company’s products include imetelstat, a telomerase inhibitor that is in clinical trials for the treatment of hematologic malignancies, and mocetinostat, a HDAC inhibitor that is in clinical trials for the treatment of cutaneous T-cell lymphoma. Geron also has a portfolio of preclinical and clinical stage programs that are focused on cancer and other age-related diseases.
– Stealth BioTherapeutics Corp ($NASDAQ:MITO)
InVivo Therapeutics Holdings Corp is a medical device company that develop, manufactures and commercializes biopolymer scaffolds to treat spinal cord injuries. The company has a market cap of 4.54M as of 2022 and a return on equity of -60.61%. The company’s products are designed to provide a scaffold for the regeneration of the spinal cord, which is then intended to improve functional recovery following a spinal cord injury.
– InVivo Therapeutics Holdings Corp ($NASDAQ:NVIV)
Stella Pharma Corp is a Japanese pharmaceutical company with a market cap of 15.74B as of 2022. The company has a Return on Equity of -15.41%. Stella Pharma is a research and development-oriented company that engages in the manufacture, sale, and import/export of ethical drugs and general drugs. The company was founded in 1951 and is headquartered in Tokyo, Japan.
Summary
GERON CORPORATION experienced a sharp decrease in total revenue for the second quarter of 2023 compared to the same period in the previous year. Net income also declined to -49.2 million from -28.1 million in the previous year. These results could be a cause of concern for investors, suggesting sluggish growth and an uncertain future. Investors should further analyze the company’s performance and prospects before making any investment decisions.
Related Posts
Recent Posts
